7*24 Hotline：
Shenzhen Hanyu Pharmaceutical Co., Ltd. (300199)
Shenzhen Hanyu Pharmaceutical Co., Ltd. was founded in April, 2003, and is a "national high-tech enterprise" specializing in the research and development, production and sales of polypeptide drugs. The company was listed on Shenzhen Stock Exchange in 2011 (abbreviated as Hanyu pharmaceutical industry, with the securities code of 300199), with a registered capital of about 917 million yuan. Hanyu pharmaceutical company is divided into Pingshan Branch, Longhua Branch, Wuhan subsidiary, Wuhan Sales Company, Hong Kong subsidiary, German subsidiary, Gansu Chengji subsidiary and Yunnan subsidiary. Its business covers the field of medicine and medical devices. Its main products include peptide preparation, polypeptide raw material medicine, customer peptide, solid preparation, drug combination packaging and medical equipment series.
The company has 22 polypeptide preparation approval numbers, 9 new drug certificates and 17 clinical approval documents. Many API and preparations of the company have been sold to Europe and America through GMP certification and inspection of the United States, EU, Korea and so on. The production base of peptide injection of Pingshan Branch has passed the certification of cGMP of EU, and has established marketing network in many countries.
As a national high-tech enterprise, the company has established Guangdong Provincial Research and development center of polypeptide drug engineering technology, National Joint Engineering Laboratory of polypeptide drugs, national public Experimental Center for peptide innovation drugs, national pilot technology platform for preparation of peptide drugs, and production base of national high-tech industrialization demonstration project, and has undertaken a number of national level projects, and has undertaken many national projects for many years It has won special science and technology awards at the national, provincial and municipal levels. Hanyu pharmaceutical industry has been awarded many years of awards, including: second prize of National Technology Invention Award, Forbes China potential enterprise, excellent patent award in China, national intellectual property advantage enterprise, top 100 tax paying enterprise, Guangdong science and technology award, Guangdong Intellectual Property demonstration enterprise, Guangdong top 500 enterprises, top 100 private enterprises in Guangdong Province, top 100 manufacturing industry in Guangdong Province, Guangdong Province The provincial government should abide by the contract and pay attention to the credit enterprise, independent innovation benchmarking enterprise, Nanshan District People's Government Quality Award, etc.
Based on polypeptide drugs and combining high-end chemicals and injection devices, the company is committed to the research and development of slow disease drugs such as diabetes, cardiovascular disease, multiple sclerosis, etc., and focuses on expanding the health industry, improving the quality of life and drug safety of patients with chronic diseases, and realizing diversified operation under the product leading strategy. The company actively explores the integration of drugs, devices and mobile Internet, and at the same time, implements the strategy of "double wheel drive" with both connotative development and extension development, grasps the national industry integration policy, increases the application of capital market and financial instruments, selects high-quality enterprises and projects, pushes forward integration and merger and reorganization, promotes the modernization, intensification and efficiency of the company's business system, and promotes the promotion of integration and reorganization The company will continue, stably, rapidly, healthily and efficiently develop, laying a solid foundation for realizing the strategic development goals of the slow disease management experts, and ensuring the company will enter a sustainable and rapid growth development channel in the future.
oil wellhead